Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Executive Summary

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18
Advertisement

Related Content

Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade

Topics

Advertisement
UsernamePublicRestriction

Register

PS051395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel